Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + epirubicin versus paclitaxel + carboplatin as neoadjuvant therapy for locally advanced breast cancer
ChiCTR-TRC-14004142Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Paclitaxel plus epirubicin with Paclitaxel plus carboplatin (2 arms). Primary endpoint: Efficacy. Started Apr 2012; status: recruiting.
02
Drugs
paclitaxelepirubicincarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-14004142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004142.